Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q32 Bio Inc.FIXX · Entity 5594 | Director · See Remarks | September 06, 2023 | September 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q32 Bio Inc.
Report date September 06, 2023 · Filed September 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,874 |
Ending reported balance
After 2023-09-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-06 · Exercise / conversion · Acquired 4,620 · Balance 152,322 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Row 2 · 2023-09-06 · Sale · Disposed 1,448 · Balance 150,874 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,380 |
Reported balance
After 2023-09-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-06 · Exercise / conversion · Disposed 4,620 · Balance 9,380 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3: The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
F3: The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2023 Filed Sep 8, 2023 20:44 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047302 · ownership.xml · derivative · entry 3 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,380 Underlying: Common Stock · 4,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:44 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 1,448 | $1.15 | $1,665.49 |
DisclosureSEC source: 0000950170-23-047302 · ownership.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,874 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:44 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 4,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-047302 · ownership.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006206 · doc4.xml · derivative · entry 2 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 632,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0000899243-23-006206 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,000 Underlying: Common Stock · 632,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 3,620 | $1.39 | $5,033.25 |
DisclosureSEC source: 0000899243-23-001575 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,166 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.39 to $1.40. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 2. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:35 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 6,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000629 · doc4.xml · derivative · entry 4 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,070 Underlying: Common Stock · 6,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. F4 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:35 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 4,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000629 · doc4.xml · derivative · entry 3 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,420 Underlying: Common Stock · 4,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F3 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:35 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000629 · doc4.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:35 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 4,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000629 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 3,920 shares acquired under Issuer's Employee Stock Purchase Plan on August 31, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030658 · doc4.xml · derivative · entry 2 Seymour Albert · CIK 0001735324 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0000899243-22-030658 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-09-06 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following September 6, 2022. Read SEC document |
| April 21, 2022 Filed Apr 21, 2022 21:31 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-22-015323 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-04-21 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following April 21, 2022. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008060 · doc4.xml · derivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 128,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0000899243-22-008060 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 128,000 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments on the first day of each calendar month following January 1, 2022. Read SEC document |
| January 05, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 1,661 | $3.78 | $6,278.75 |
DisclosureSEC source: 0000899243-22-001746 · doc4.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,646 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.79. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 4,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001746 · doc4.xml · derivative · entry 3 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,710 Underlying: Common Stock · 4,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F4 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 4,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001746 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:25 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005461 · doc4.xml · derivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:25 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0000899243-21-005461 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-02-05 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 5,103 | $12.05 | $61,469.21 |
DisclosureSEC source: 0000899243-21-001153 · doc4.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,017 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,897 | $12.06 | $119,395.43 |
DisclosureSEC source: 0000899243-21-001153 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,120 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 10,000 | $11.44 | $114,422.00 |
DisclosureSEC source: 0000899243-21-000891 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,017 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.25 to $11.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,133 | $20.50 | $187,216.45 |
DisclosureSEC source: 0000899243-20-000314 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,017 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $20.4100 to $20.6800. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $19.92 | $0.00 |
DisclosureSEC source: 0000899243-19-029156 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2029-12-11 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2020. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,300 | $16.23 | $150,969.69 |
DisclosureSEC source: 0000899243-19-028392 · doc4.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,150 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.04 to $16.355. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,300 | $16.06 | $149,389.62 |
DisclosureSEC source: 0000899243-19-028392 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,450 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 100 | $18.23 | $1,823.00 |
DisclosureSEC source: 0000899243-19-024656 · doc4.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,750 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:07 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,200 | $17.38 | $159,936.48 |
DisclosureSEC source: 0000899243-19-024656 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,850 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.09 to $17.85. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:40 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,300 | $18.74 | $174,283.86 |
DisclosureSEC source: 0000899243-19-022840 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,050 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.29 to $19.06. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:18 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,300 | $17.37 | $161,523.33 |
DisclosureSEC source: 0000899243-19-020993 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,350 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.87 to $17.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:32 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 100 | $19.56 | $1,956.00 |
DisclosureSEC source: 0000899243-19-019182 · doc4.xml · nonDerivative · entry 2 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,650 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:32 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,200 | $18.98 | $174,582.88 |
DisclosureSEC source: 0000899243-19-019182 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,750 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.52 to $19.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:11 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 9,300 | $19.90 | $185,093.25 |
DisclosureSEC source: 0000899243-19-015647 · doc4.xml · nonDerivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,950 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.45 to $20.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:27 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 74,000 | $0.00 Strike: $24.28 | $0.00 |
DisclosureSEC source: 0000899243-18-031346 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2028-12-14 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2019. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 23:28 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 66,501 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008926 · doc4.xml · derivative · entry 1 Seymour Albert · CIK 0001735324 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,501 Underlying: Common Stock · 66,501 shares Expires 2028-03-27 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.